M&A
Mentari closes InMed merger and $490 million financing, lists on Nasdaq as MTRI
Migraine-prevention developer Mentari Therapeutics has finished combining with InMed Pharmaceuticals and started trading under the ticker MTRI. Its $490 million in private financing, which includes $50 million of converted notes, is expected to fund operations into 2029. First Phase 1 data for MT-001 are due in mid-2027, and MT-002 is set for a regulatory filing in early 2027.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.